Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma

Sergio Giralt • 17 Feb 2023
Tandem Meetings 2023
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa-3

In this video, Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the results of the KarMMa-3 study (NCT03651128), a Phase III trial comparing idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple class–exposed relapsed/refractory (R/R) multiple myeloma. The study reported a significant benefit for ide-cel in terms of complete remission (CR) rate and progression-free survival (PFS) across all risk categories. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals